Johns Hopkins Medicine Treats First Commercial TULSA-PRO(TM) Case

Executive Summary

• Profound Medical announced that The Johns Hopkins Hospital treated its first non‑clinical‑trial prostate cancer patient using the TULSA‑PRO® system, marking the official launch of the technology at a leading academic medical center.
• The treatment was performed in Johns Hopkins Medicine’s newly opened interventional MRI (iMRI) suite, highlighting the integration of real‑time therapeutic MRI platforms.
• CEO Arun Menawat emphasized the significance of this partnership given Johns Hopkins’ early involvement in TULSA‑PRO’s pivotal trials and its role in post‑market studies.

Key Details

• Milestone: First non‑clinical‑trial prostate cancer patient treated with TULSA‑PRO® at Johns Hopkins Hospital.
• Location: New interventional MRI (iMRI) suite at Johns Hopkins Medicine, enabling real‑time MR‑guided procedures.
• Technology Overview:
• AI‑powered, MRI‑guided, incision‑free therapy delivering robotically controlled directional ultrasound via the urethra.
• Real‑time MR thermography provides continuous temperature monitoring and autonomous adjustment (target 55‑57 °C).
• Clinical benefits include no procedural blood loss, no overnight hospital stay, rapid recovery, and reduced risk of urinary incontinence or erectile dysfunction.
• Clinical Context: TULSA‑PRO is FDA 510(k) cleared, CE marked, and Health Canada approved for treatment of prostate cancer across risk levels and benign prostatic hyperplasia (BPH).
• CEO Quote: “We are thrilled to see Johns Hopkins Medicine now offer TULSA‑PRO to their patients… the implementation of TULSA‑PRO in a newly built interventional MR suite specifically designed for surgical procedures that benefit from the precision of real‑time MRI… is a growing movement.” – Arun Menawat, CEO & Chairman.
• Additional Portfolio: Profound also commercializes Sonalleve®, a CE‑marked platform for uterine fibroids, adenomyosis, bone metastasis pain palliation, desmoid tumors, and osteoid osteoma; it holds approvals in China and a Humanitarian Device Exemption in the U.S.

Notable Quotes

• “The implementation of TULSA‑PRO in a newly built interventional MR suite… is not surprising that a leading institution such as Johns Hopkins Medicine is at the forefront of this trend.” – Arun Menawat, CEO and Chairman, Profound Medical.